Five Pfiz­er drugs among first 27 now sub­ject to Medicare in­fla­tion re­bates, HHS says

The De­part­ment of Health and Hu­man Ser­vices (HHS) on Wednes­day un­veiled the first set of 27 Part B pre­scrip­tion drugs, in­clud­ing five from Pfiz­er, that will be sub­ject to Medicare in­fla­tion re­bates be­cause their prices rose faster than the rate of in­fla­tion.

Se­niors re­ceiv­ing the physi­cian-ad­min­is­tered drugs be­gin­ning in April will have low­er coin­sur­ance for these drugs (list­ed be­low) and HHS said they may see their out-of-pock­et costs for these drugs de­crease by as much as $390 per av­er­age dose.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER